Category: ProMIS Neurosciences

PROMIS NEUROSCIENCES AND BC NEUROIMMUNOLOGY ANNOUNCE REVENUE-SHARING JOINT VENTURE AGREEMENT TO DEVELOP AND OFFER BLOOD-BASED DIAGNOSTIC TESTS FOR ALZHEIMER’S DISEASE

TORONTO, Ontario and CAMBRIDGE, Mass. — July 9, 2020 —ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets (peptide antigens) on the molecular surface of complex, misfolded proteins, and BC Neuroimmunology Lab (BCNI), have entered into a revenue-sharing joint venture (JV) agreement to develop and offer highly …

Continue reading

PROMIS NEUROSCIENCES AND COLLABORATIVE TEAM RECEIVE SUPERCLUSTER AWARD SUPPORTING AVOIDANCE OF FUTURE PANDEMICS BY NEW STRAINS OF THE COVID-19 VIRUS

TORONTO, Ontario and CAMBRIDGE, Mass. —May 28, 2020— ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique core technology to predict novel targets on the molecular surface of complex proteins, together with a team of commercial and academic collaborators, have received a Digital Technology Supercluster award from the Government of Canada for 1.8 million …

Continue reading

PROMIS NEUROSCIENCES IDENTIFIES MULTIPLE NOVEL TARGETS ON SARS COV-2 FOR DEVELOPMENT OF A HIGHLY ACCURATE COVID-19 ANTIBODY TEST

TORONTO, Ontario and CAMBRIDGE, Mass.— May 12, 2020—ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for detection of antibodies to SARS CoV-2, the causative agent of COVID-19. MORE>>

PROMIS NEUROSCIENCES ANNOUNCES COLLABORATION TO DEVELOP SEROLOGICAL TEST TO ASSESS COVID-19 IMMUNITY

TORONTO, Ontario and CAMBRIDGE, Mass. – April 15, 2010 – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with a unique, core technology to predict novel targets on the molecular surface of complex proteins, announced today a collaboration with Dr. Hans Frykman and his team to develop a high-throughput, highly specific serological assay to accurately …

Continue reading

JOURNAL OF THE AMERICAN ACADEMY OF NEUROLOGY PUBLISHES PROMIS NEUROSCIENCES’ ABSTRACTS ON NOVEL ANTIBODY CANDIDATES

TORONTO, Ontario and CAMBRIDGE, Mass. —April 9, 2020 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers of proteins implicated in the development of neurodegenerative diseases, announced today that the journal Neurology will publish AAN abstracts of data that demonstrate the strength of its …

Continue reading